GrumpyGigDriver 🇺🇲🇺🇸🔞💸🎲🏈🎆🎇🧨✨

I just invited you to earn with Uber. Earn at least $1,374 for your first 151 passenger trips in 30 days. 🤑 💲💲💲💲💲🤑💵💵💵💵💵 🎉🎉🎉 #job #sidegig #gigoftheday #WONDERING drivers.uber.com/i/dbs4a1g

BREAKING : Trump is exposed again 🍿 Trump at 2:15 PM 🇺🇸: Saudi Prince MBS is encouraging us to do a lot of thing with Iran. He is with us in the fight Saudi at 2:20 PM 🇸🇦: "Our leadership isn't encouraging Trump to prolong war against Iran" 😂 Honesty : 00%, Lies : 100% 😭

With his Strawberry Shortcake bedding which is his daughters Ivanka's. He just got done molesting her.

VoteHub projects Emily Gregory to win the Florida State House District 87 general election.

“Those are the words of a potential war criminal.”

Donald Trump will now be represented by a Democrat in the Florida House of Representatives. Emily Gregory just flipped the Trump +11 seat that includes Mar-a-Lago. 🇺🇸

DO NOT STOP TALKING ABOUT THE EPSTEIN FILES DO NOT STOP TALKING ABOUT THE EPSTEIN FILES DO NOT STOP TALKING ABOUT THE EPSTEIN FILES DO NOT STOP TALKING ABOUT THE EPSTEIN FILES DO NOT STOP TALKING ABOUT THE EPSTEIN FILES DO NOT STOP TALKING ABOUT THE EPSTEIN FILES DO NOT STOP TALKING ABOUT THE EPSTEIN FILES DO NOT STOP TALKING ABOUT THE EPSTEIN FILES

BREAKING — Donald Trump will now be represented by a Democrat in the Florida State House. Democrats flip Trump+11 FL HD-87 in a major upset, continuing their recent special election surge. It’s their third flip this month — and eighth of the Trump presidency.

@lyft #Uber #GigEconomy #GasPrices #DriverPay #Rideshare #NewOrleans

Gas prices are up, but driver pay isn't keeping pace. ⛽️📈 It’s time to bring back the $1.00 fuel surcharge per trip. Drivers shouldn't have to absorb the cost of a volatile market just to keep our cities moving. Fair pay for the people behind the wheel! #GasPrices #Rideshare

#Amazon shares sink 10% afterhours after earnings miss, $200 billion spending plan cnbctv18.com/market/amazon-…

I just invited you to earn with Uber. Earn at least $2,040 for your first 179 passenger trips in 30 days. drivers.uber.com/i/kt2e6p2

@BiotechInvqgt0 Not at the moment, but they will surely seek better financing terms. For now, they have a 12-month runway, according to what management mentioned in the last conference call.

$HUMA Humacyte doesn’t need more cash? investors.humacyte.com/static-files/f…

Humacyte’s ATEV Evaluated After Long-Term Clinical Use | @humacyte evtoday.com/news/humacytes…

@elonmusk Elon can you invest in a stock called humacyte ?

$HUMA BTIG Humacyte, Inc. (HUMA) Buy, $6 PT Takeaways from VEITH KOL Event; Feedback Remains Encouraging What You Should Know: We attended HUMA's ATEV Interactive Program at the Vascular And Endovascular Issues, Techniques and Horizons (VEITH) Symposium in New York where several clinicians spoke about their experience using Symvess for vascular trauma. Reviewing both clinical data and a series of cases, the KOLs spoke to their real-world experience with Symvess and provided insights on patient outcomes. Overall, the clinician enthusiasm for Symvess is evident from our discussions with physicians at the symposium and reaffirms what we've heard from other KOLs (here) previously. We view this as encouraging as HUMA progresses through the early commercial rollout of Symvess. We expect positive feedback will continue as HUMA works to build its body of evidence highlighting Symvess' clinical safety and efficacy. We summarize several of these studies and provide an update on the commercial launch below. Long Term Ukraine Data: In early October, HUMA announced the publication of long-term results from its humanitarian program using Symvess to treat wartime vascular trauma injuries in Ukraine in Oxford Academic’s Military Medicine. The results showed wartime injuries treated with Symvess were observed to have a continued high rate of patency (87.1%), 100% limb salvage, and zero cases of conduit infection in 17 patients with extremity injuries followed for up to 18 months. Additionally, one of the KOL's at the event presented a case study (see p. 3 for details) with ~24 month follow-up data from a patient treated in the Ukrainian humanitarian program that confirmed primary patency of Symvess with no stenosis, no claudication, and stable limb function. Additional publications of note: In late October, a study was published in the American Association for the Surgery of Trauma (AAST)'s Trauma Surgery & Acute Care Open Journal comparing clinical outcomes of Symvess to autologous vein in the treatment of extremity arterial trauma. Patients from two of HUMA's studies, V005 and V017, were matched to patients from the Prospective Observational Vascular Injury Treatment (PROOVIT) registry. The study found patients treated with Symvess had statistically similar clinical outcomes to those for patients from the PROOVIT registry who received autologous vein. Primary patency for Symvess vs. autologous vein was 86.6% vs. 91.8%; secondary patency was 91.0% vs. 97.7%; amputation was 7.5% vs. 8.2%; conduit infection was 1.5% vs. 0%; and death was 4.5% vs. 4.5%, respectively. Symvess launch underway: To date, ~16 hospitals have ordered Symvess with the majority of facilities reordering. ~25 VACs (inclusive of multi-hospital networks) have approved Symvess, bringing the total number of civilian hospitals with access to ~92 (+10 from 2Q25). Additionally, ~45 VACs have initiated the review process. Given Symvess is now included on the Electronic Catalog (ECAT), ~190 military treatment facilities and as well as VA hospitals are eligible to purchase Symvess. HUMA noted it has made its first Symvess sale in a military facility since its inclusion on the ECAT. Recall that HUMA lowered Symvess' price to ~$24,250 in July. We estimate that HUMA sold ~29 units this quarter, up from ~4 in 2Q25

$HUMA [1.19$] [6.22%] [November 21, 2025] Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results

@jrouldz Recellularizatuon! Waiting on a big military contract investors.humacyte.com/node/10291/pdf

#Humacyte is revolutionizing the treatment of vascular and organ-related diseases by developing and manufacturing implantable, bioengineered human tissues Their Stock is currently trading at $1.26 And I believe this is an insane buying opportunity Price Target $10 $HUMA

@SalimoAnne Hello how is everyone

Say Hi 👋 Lets Follow You"